FGFR Inhibitor Shows Preclinical Activity in Breast Cancer
This video highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.
In this video, Dominik Mumberg, PhD, of Bayer AG in Berlin, highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.
The data were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy
April 28th 2024Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.
